134965-39-2

Upstream product

• 21577-50-4 mucobromic acid 
• 20570-96-1 benzylhydrazine dihydrochloride 
• 100-39-0 benzyl bromide 
• 488-11-9 mucobromic acid 
• 555-96-4 Benzylhydrazine 
• 5788-58-9 4,5-dibromo-3(2H)pyridazinone 
• 100-44-7 benzyl chloride 

Downstream Products

• 128457-14-7 2-Benzyl-4-bromo-5-(N-methyl-hydrazino)-2H-pyridazin-3-one 
• 856250-23-2 2-benzyl-4,5-bis(4-chlorophenyl)pyridazin-3(2H)-one 
• 1200133-67-0 2-benzyl-5-bromo-4-[hydroxy(diphenyl)methyl]pyridazin-3(2H)-one 
• 415713-55-2 2-benzyl-4,5-bis(methylthio)pyridazin-3(2H)-one 
• 1200133-65-8 2-benzyl-5-bromo-4-[hydroxy(phenyl)methyl]pyridazin-3(2H)-one 
• 1200133-49-8 2-benzyl-5-(dimethylamino)-3-oxo-2,3-dihydropyridazine-4-carbaldehyde 
• 1200133-66-9 2-benzyl-5-bromo-3-oxo-2,3-dihydropyridazine-4-carbaldehyde 
• 1200133-64-7 2-benzyl-5-bromo-4-deuteropyridazin-3(2H)-one 
• 912820-23-6 2-benzyl-5-bromopyridazin-3(2H)-one 
• 1549706-97-9 5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-2-benzyl-4-bromopyridazin-3(2H)-one 
• 476172-04-0 2-benzyl-pyridazino[4,5-c]isoquinolin-1(2H)-one 
• 476171-99-0 3-benzyl-pyridazino[4,5-c]isoquinolin-4(3H)-one 
• 1346155-93-8 2-benzyl-4-bromo-5-(triphenylphosphoranylideneamino)pyridazin-3(2H)-one 
• 1346155-76-7 5-azido-2-benzyl-4-bromopyridazin-3(2H)-one 

Relevant academic research and scientific papers

Synthesis of functionalized pyridazin-3(2 H)-ones via nucleophilic substitution of hydrogen (SNH)

Reaction of 2-benzyl-5-halopyridazin-3(2H)-ones (3) with Grignard reagents followed by quenching with electrophiles unexpectedly yielded 4,5-disubstituted pyridazin-3(2H)-ones instead of 5-substituted pyridazin-3(2H)-ones. These reactions represent the fi

Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase

The synthesis, structure-activity relationship and modeling of a series of 5-substituted-N-aryl pyridazinone based p38α inhibitors are described. In comparing the series to the similar N-aryl pyridinone series, it was found that the pyridazinones maintain

Synthesis of functionalized pyridazin-3(2H)-ones via bromine-magnesium exchange on bromopyridazin-3(2H)-ones

(Chemical Equation Presented) The potential of halogen-magnesium exchange reactions, followed by quenching with electrophiles, for the functionalization of the pyridazin-3(2H)-one core was investigated. 2-Benzyl-4-bromo-5-methoxy- (1), 2-benzyl-5-bromo-4-

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.

Substituted pyridazinones

Disclosed are substituted pyridazinones that are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical composition containing the pyridazinone compounds, methods of preparing th

PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the pyridazin-3-one compounds of formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a

Synthesis of 4-aryl-5-hydroxy- and 5-aryl-4-hydroxypyridazin-3(2H)-ones and their use in the preparation of 4,5-diarylpyridazin-3(2H)-ones and hitherto unknown isochromeno[3,4-d]pyridazinediones

Easily accessible 2-substituted 4-aryl-5-methoxy- and 2-substituted 5-aryl-4-methoxypyridazin-3(2H)-ones were transformed into the corresponding aryl-hydroxypyridazin-3(2H)-ones by alkaline hydrolysis. The use of these compounds in the synthesis of 2-substituted 4,5-diarylpyridazin-3(2H)-ones with two differently substituted aryl groups was investigated. Two aryl-hydroxypyridazin-3(2H)-ones, 2-(2-benzyl-5-hydroxy-3-oxo-2,3-dihydropyridazin-4-yl)benzaldehyde and 2-(1-benzyl-5-hydroxy-6-oxo-1,6-dihydropyridazin-4-yl)benzaldehyde, were transformed into 2-benzyl-1H-isochromeno[3,4-d]pyridazine-1,6(2H)-dione and 3-benzyl-3H-isochromeno[3,4-d]pyridazine-4,6-dione, respectively, via oxidation of the formyl group with KMnO4 followed by lactonization.

Prostaglandin endoperoxide H synthase biosynthesis inhibitors

The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

Pyridazinones as inhibitors of cyclooxygenase-2

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

Novel Heterocyclization of Hydrazinopyridazinones with Dimethyl Acetylenedicarboxylate with Dehydrogenation and Rearrangement

5-Hydrazinopyridazin-3(2H)-ones 1 reacted with dimethyl acetylenedicarboxylate 2 to give 4,6-dihydropyridazinopyridazin-5-(1H)-ones 3 by cyclization with dehydrogenation.On the other hand, the reaction of 4-bromo-5-hydrazino- and 5-bromo-4-hydrazin